1. Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge
- Author
-
Wei Wang, Lianqun Qiu, Shaoying Li, Carlos E. Bueso-Ramos, Mahsa Khanlari, Roberto N. Miranda, C. Cameron Yin, L. Jeffrey Medeiros, Jie Xu, Pei Lin, Guilin Tang, and M. James You
- Subjects
Pathology ,medicine.medical_specialty ,biology ,medicine.diagnostic_test ,business.industry ,Not Otherwise Specified ,BCL6 ,medicine.disease ,Blastoid ,biology.organism_classification ,Pathology and Forensic Medicine ,Lymphoma ,medicine.anatomical_structure ,Immunophenotyping ,Medicine ,Bone marrow ,business ,B-cell lymphoma ,Fluorescence in situ hybridization - Abstract
The 2016 WHO classification introduced the category of high-grade B-cell lymphoma (HGBL), which includes one poorly understood subset, blastoid-HGBL. Establishing the diagnosis and distinguishing blastoid-HGBL from B-acute lymphoblastic leukemia (B-ALL) in bone marrow can be challenging. We assessed 31 cases of blastoid-HGBL diagnosed initially in bone marrow and compared this group to 36 cases of B-ALL using immunophenotyping, fluorescence in situ hybridization, and targeted next generation sequencing analysis. The 31 blastoid-HGBL cases included 14 HGBL with MYC and BCL2 and/or BCL6 rearrangements (double hit lymphoma, DHL), 13 HGBL, not otherwise specified (NOS), and four cases with TdT expression that were difficult to classify. Compared with B-ALL, blastoid-HGBL cases more often showed increased intensity/bright expression of CD20, CD38, CD45, BCL-6, and MYC, and less frequent bright expression of CD10 and TdT. Cases of blastoid-HGBL also more frequently had MYC rearrangement, a complex karyotype and TP53 mutation (p
- Published
- 2022